ESMO attendees were treated to the results from 2 fantastic studies from Spain investigating genomic signatures in sinonasal cancers (SNCs), neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs).

As the year draws to an end, the ARC Portal, would like to acknowledge and thank all the people that have contributed to making 2023 another amazing year.

The ARC Portal is encouraging all health-decision makers in Australia to read the newest report “Rarefication: Personalised medicine in the genomic revolution” from Rare Cancers Australia.

The responses to the Senate Inquiry into equitable access to diagnosis and treatment for individuals with rare and less common cancers are now available to read on the Parliament of Australia website.